Phase I Trial of Anti-Vascular Endothelial Growth Factor/Anti-angiopoietin 2 Bispecific Antibody faricimab for Neovascular Age-Related Macular Degeneration

Up to 350 words. No references allowed. Abstracts may be submitted at a later date.